Recipharm AB Appoints Prof. Hans Lennernas to One of Its Operating Boards
Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of 24.5 MEuro. His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.
Dr. Lennernäs has served as the Principal Investigator in an extensive collaboration with the Food Drug & Administration, USA, University of Michigan, USA, and Medical Product Agency, Sweden over the course of several years in which he developed a new guideline for the Biopharmaceutics Classification System. He has established an extensive and widely used human permeability database.
In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.
“I am very much looking forward to serving on the Board of Directors at Recipharm Pharmaceutical Development AB. Indeed, this is a company with an excellent track record and an impressive long term strategy in place”, Hans Lennernäs commented.
“We are very pleased to welcome a Board Member of Hans Lennernäs calibre”, remarked General Manager Maria Lundberg. “His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the Board. I look forward to Recipharm benefiting from his Board level contribution and insights that will help the company perpetuate its track record of commercial success”.
About Recipharm
Recipharm AB is a leading contract development and manufacturing organisation (CDMO) based in Sweden employing some 1,700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers.
Recipharm’s Pharmaceutical Development Services group offer services from straight forward manufacture of clinical trial material through to more complex product development and formulation. From our pharmaceutical development centre we can work on a variety of technologies, including sterile products. Formulation development, analytical method development and stability studies are all core activities.
For more information visit; www.recipharm.com
Contact information
Recipharm – Maria Lundberg, General Manager, +46 8 602 52 73
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:
E-mail: t.jervis@defacto.com or a.heeley@defacto.com
Tel: +44 (0) 207 861 3019/3043